BioVie To Present of NE3017 in Alzheimer s Disease Data at 83rd Scientific Sessions of the American Diabetes Association tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
TORONTO, Ontario and CAMBRIDGE, Massachusetts - - ProMIS Neurosciences Inc. , a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded. | May 16, 2023
15.05.2023 - Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s diseasePresented preclinical data supporting target identification and candidate differentiation across pipeline of antibody .
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term. | May 11, 2023